Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

Clearside Biomedical Inc. said the drug developer’s treatment helped improve vision in patients with fluid buildup in the eye in a late-stage study.

A biosimilar version of AbbVie Inc.’s blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc. and Samsung Biologics, was approved by EU regulators.

The EMA’s CHMP granted a positive opinion for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients from 2 years of age.

Eleven Biotherapeutics struck a $270 million deal with Roche to develop Eleven’s experimental EBI-031 treatment for eye-related diseases.